Physician profile
Rebekah Epperly
NPI 1174299879
$2,693.41
in general payments reported to CMS, 2019-2025
20 companies · $780 in 2025
The $780 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $56.58 · 2022: $419 · 2023: $737 · 2024: $700 · 2025: $780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,217.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,291.38 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $209.25 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $174.13 | 2023-2025 | Xarelto, Spravato |
| Abbvie INC. | $160.11 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $110.82 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $108.23 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.72 | 2022-2025 | |
| Glaxosmithkline, LLC. | $78.67 | 2022-2025 | Shingrix, Arexvy, Pediarix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.90 | 2021-2025 | Tradjenta, Jardiance |
| Biohaven Pharmaceutical Holding Company Ltd. | $66.90 | 2022 | |
| Dexcom, INC. | $54.37 | 2022-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.11 | 2023-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $46.44 | 2024-2025 | Voquezna |
| Sumitomo Pharma America, INC. | $42.53 | 2024 | Gemtesa |
| Exact Sciences Corporation | $33.93 | 2024-2025 | Cologuard Collection Kit |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $31.98 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $25.84 | 2023 | Rexulti |
| Astellas Pharma US INC | $18.02 | 2024 | Veozah |
| Amgen INC. | $15.96 | 2024 | Krystexxa |
| Idorsia Pharmaceuticals US INC | $13.12 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebekah Epperly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.